Multivariable analysis to determine factors associated with odds of stopping IBD medication in IBD patients with COVID-19.
| Effect . | Crude odds ratio . | 95% Wald . | p-value . | Adjusted odds ratio . | 95% Wald . | p-value . | ||
|---|---|---|---|---|---|---|---|---|
| . | . | confidence limits . | . | . | . | confidence limits . | . | . |
| Active vs remission | 1.024 | 0.822 | 1.277 | 0.8296 | 0.971 | 0.772 | 1.221 | 0.8003 |
| Unknown vs remission | 1.203 | 0.676 | 2.14 | 0.5298 | 1.261 | 0.702 | 2.266 | 0.4375 |
| UC/IBDU vs CD | 0.607 | 0.489 | 0.755 | <0.0001 | 0.597 | 0.478 | 0.747 | <0.0001 |
| USA vs non-USA | 0.929 | 0.742 | 1.163 | 0.5203 | 0.943 | 0.704 | 1.264 | 0.6965 |
| Spain vs non-Spain | 1.053 | 0.783 | 1.417 | 0.7311 | 1.13 | 0.791 | 1.615 | 0.5015 |
| France vs non-France | 1.048 | 0.671 | 1.636 | 0.8361 | 1.029 | 0.63 | 1.68 | 0.9092 |
| Italy vs non-Italy | 0.507 | 0.289 | 0.892 | 0.0183 | 0.595 | 0.326 | 1.087 | 0.0916 |
| UK vs non-UK | 1.099 | 0.67 | 1.803 | 0.7081 | 1.154 | 0.674 | 1.975 | 0.6014 |
| Iran vs non-Iran | 1.154 | 0.655 | 2.032 | 0.6205 | 1.403 | 0.764 | 2.577 | 0.2748 |
| Russia vs non-Russia | 1.308 | 0.824 | 2.078 | 0.2544 | 1.477 | 0.882 | 2.472 | 0.1381 |
| Brazil vs non-Brazil | 1.785 | 1.014 | 3.141 | 0.0447 | 1.731 | 0.947 | 3.167 | 0.0748 |
| Effect . | Crude odds ratio . | 95% Wald . | p-value . | Adjusted odds ratio . | 95% Wald . | p-value . | ||
|---|---|---|---|---|---|---|---|---|
| . | . | confidence limits . | . | . | . | confidence limits . | . | . |
| Active vs remission | 1.024 | 0.822 | 1.277 | 0.8296 | 0.971 | 0.772 | 1.221 | 0.8003 |
| Unknown vs remission | 1.203 | 0.676 | 2.14 | 0.5298 | 1.261 | 0.702 | 2.266 | 0.4375 |
| UC/IBDU vs CD | 0.607 | 0.489 | 0.755 | <0.0001 | 0.597 | 0.478 | 0.747 | <0.0001 |
| USA vs non-USA | 0.929 | 0.742 | 1.163 | 0.5203 | 0.943 | 0.704 | 1.264 | 0.6965 |
| Spain vs non-Spain | 1.053 | 0.783 | 1.417 | 0.7311 | 1.13 | 0.791 | 1.615 | 0.5015 |
| France vs non-France | 1.048 | 0.671 | 1.636 | 0.8361 | 1.029 | 0.63 | 1.68 | 0.9092 |
| Italy vs non-Italy | 0.507 | 0.289 | 0.892 | 0.0183 | 0.595 | 0.326 | 1.087 | 0.0916 |
| UK vs non-UK | 1.099 | 0.67 | 1.803 | 0.7081 | 1.154 | 0.674 | 1.975 | 0.6014 |
| Iran vs non-Iran | 1.154 | 0.655 | 2.032 | 0.6205 | 1.403 | 0.764 | 2.577 | 0.2748 |
| Russia vs non-Russia | 1.308 | 0.824 | 2.078 | 0.2544 | 1.477 | 0.882 | 2.472 | 0.1381 |
| Brazil vs non-Brazil | 1.785 | 1.014 | 3.141 | 0.0447 | 1.731 | 0.947 | 3.167 | 0.0748 |
Statistically significant associations are in bold.
UC, ulcerative colitis; IBD-U, IBD-unspecified; CD, Crohn’s disease.
Multivariable analysis to determine factors associated with odds of stopping IBD medication in IBD patients with COVID-19.
| Effect . | Crude odds ratio . | 95% Wald . | p-value . | Adjusted odds ratio . | 95% Wald . | p-value . | ||
|---|---|---|---|---|---|---|---|---|
| . | . | confidence limits . | . | . | . | confidence limits . | . | . |
| Active vs remission | 1.024 | 0.822 | 1.277 | 0.8296 | 0.971 | 0.772 | 1.221 | 0.8003 |
| Unknown vs remission | 1.203 | 0.676 | 2.14 | 0.5298 | 1.261 | 0.702 | 2.266 | 0.4375 |
| UC/IBDU vs CD | 0.607 | 0.489 | 0.755 | <0.0001 | 0.597 | 0.478 | 0.747 | <0.0001 |
| USA vs non-USA | 0.929 | 0.742 | 1.163 | 0.5203 | 0.943 | 0.704 | 1.264 | 0.6965 |
| Spain vs non-Spain | 1.053 | 0.783 | 1.417 | 0.7311 | 1.13 | 0.791 | 1.615 | 0.5015 |
| France vs non-France | 1.048 | 0.671 | 1.636 | 0.8361 | 1.029 | 0.63 | 1.68 | 0.9092 |
| Italy vs non-Italy | 0.507 | 0.289 | 0.892 | 0.0183 | 0.595 | 0.326 | 1.087 | 0.0916 |
| UK vs non-UK | 1.099 | 0.67 | 1.803 | 0.7081 | 1.154 | 0.674 | 1.975 | 0.6014 |
| Iran vs non-Iran | 1.154 | 0.655 | 2.032 | 0.6205 | 1.403 | 0.764 | 2.577 | 0.2748 |
| Russia vs non-Russia | 1.308 | 0.824 | 2.078 | 0.2544 | 1.477 | 0.882 | 2.472 | 0.1381 |
| Brazil vs non-Brazil | 1.785 | 1.014 | 3.141 | 0.0447 | 1.731 | 0.947 | 3.167 | 0.0748 |
| Effect . | Crude odds ratio . | 95% Wald . | p-value . | Adjusted odds ratio . | 95% Wald . | p-value . | ||
|---|---|---|---|---|---|---|---|---|
| . | . | confidence limits . | . | . | . | confidence limits . | . | . |
| Active vs remission | 1.024 | 0.822 | 1.277 | 0.8296 | 0.971 | 0.772 | 1.221 | 0.8003 |
| Unknown vs remission | 1.203 | 0.676 | 2.14 | 0.5298 | 1.261 | 0.702 | 2.266 | 0.4375 |
| UC/IBDU vs CD | 0.607 | 0.489 | 0.755 | <0.0001 | 0.597 | 0.478 | 0.747 | <0.0001 |
| USA vs non-USA | 0.929 | 0.742 | 1.163 | 0.5203 | 0.943 | 0.704 | 1.264 | 0.6965 |
| Spain vs non-Spain | 1.053 | 0.783 | 1.417 | 0.7311 | 1.13 | 0.791 | 1.615 | 0.5015 |
| France vs non-France | 1.048 | 0.671 | 1.636 | 0.8361 | 1.029 | 0.63 | 1.68 | 0.9092 |
| Italy vs non-Italy | 0.507 | 0.289 | 0.892 | 0.0183 | 0.595 | 0.326 | 1.087 | 0.0916 |
| UK vs non-UK | 1.099 | 0.67 | 1.803 | 0.7081 | 1.154 | 0.674 | 1.975 | 0.6014 |
| Iran vs non-Iran | 1.154 | 0.655 | 2.032 | 0.6205 | 1.403 | 0.764 | 2.577 | 0.2748 |
| Russia vs non-Russia | 1.308 | 0.824 | 2.078 | 0.2544 | 1.477 | 0.882 | 2.472 | 0.1381 |
| Brazil vs non-Brazil | 1.785 | 1.014 | 3.141 | 0.0447 | 1.731 | 0.947 | 3.167 | 0.0748 |
Statistically significant associations are in bold.
UC, ulcerative colitis; IBD-U, IBD-unspecified; CD, Crohn’s disease.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
